NASDAQ:CYCN

Cyclerion Therapeuticsinc Stock Insider Trading

etoro logo Buy CYCN
*Your capital is at risk
$3.00
-0.0200 (-0.662%)
At Close: Jun 03, 2026

Cyclerion TherapeuticsInc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -54.26. In total, the insiders bought 5.22M and sold 715.78K CYCN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-54.26
Buy 5.22M shares
Sell 715.78K shares
96% Buy Activity
Negligible or No Correlation
Buy Signal Low Confidence
Jun 01, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -54.26.
  • Confidence increased due to high data reliability score of 80.
  • Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date Type Person Role Amount
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Desouza Errol B
Director
Director 20 000
Value: $10.6K
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Mcguire Terrance
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Mendelsohn Michael
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Fanucci Marsha
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Lovell Stephanie
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Conrades George H
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Isacson Ole
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Desouza Errol B
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Desouza Errol B
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Isacson Ole
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Conrades George H
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Lovell Stephanie
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Fanucci Marsha
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Mendelsohn Michael
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Mcguire Terrance
Director 20 000
Value: $0
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Desouza Errol B
Director
Director 20 000
Value: $10.6K
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Isacson Ole
Director
Director 20 000
Value: $10.6K
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Conrades George H
Director
Director 20 000
Value: $10.6K
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Lovell Stephanie
Director
Director 20 000
Value: $10.6K
Jun 14, 2022
Buy
Stock Option (Right to Buy)
A-Award
Mcguire Terrance
Director
Director 20 000
Value: $10.6K
Jan 20, 2022
Buy
Employee Stock Option (Right to Buy)
A-Award
Busch Andreas
Chief Scientific Officer
Officer 135 000
Value: $163.4K
Jan 20, 2022
Buy
Employee Stock Option (Right to Buy)
A-Award
Gjino Anjeza
Chief Financial Officer
C-Suite Officer 135 000
Value: $163.4K
Jan 20, 2022
Buy
Employee Stock Option (Right to Buy)
A-Award
Hecht Peter M
Chief Executive Officer
CEO / President 430 000
Value: $520.3K
Jan 20, 2022
Buy
Employee Stock Option (Right to Buy)
A-Award
Gault Cheryl
Chief Operating Officer
C-Suite Officer 135 000
Value: $163.4K
Jan 20, 2022
Buy
Employee Stock Option (Right to Buy)
A-Award
Gault Cheryl
Chief Operating Officer
C-Suite Officer 135 000
Value: $163.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CYCLERION THERAPEUTICSINC.
Cyclerion TherapeuticsInc
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's dis...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE